Consider augmentation or switching strategies when first-line antidepressants are unsuccessful in major depressive disorder

被引：0
|
作者：
机构：
来源：
Drugs & Therapy Perspectives | 2011年 / 27卷 / 12期
关键词：
Amphetamines; Aripiprazole; Augmentation-therapies; Buspirone; Depression; Liothyronine; Lithium; Mianserin; Mirtazapine; Modafinil; Monoamine-oxidase-; inhibitors; Olanzapine; Pindolol; Quetiapine; Risperidone; Serotonin-uptake-; Tricyclic-antidepressants; Ziprasidone;
D O I：
10.2165/11207880-000000000-00000
中图分类号：
学科分类号：
摘要：
When treating major depressive disorder that has not responded to an adequate trial of a first-line antidepressant, the current evidence most strongly supports switching to another first-line antidepressant or augmentation with the atypical antipsychotics aripiprazole or quetiapine. Lithium and liothyronine (triiodothyronine) may be used to augment tricyclic antidepressants, but further studies of their use to augment newer antidepressants are needed. © 2011 Adis Data Information BV. All rights reserved.
引用
收藏
页码：7 / 12
页数：5
相关论文
共 50 条
  • [1] Switching, combination, and augmentation strategies for major depressive disorder
    Papakostas, George I.
    [J]. ANNALS OF CLINICAL PSYCHIATRY, 2010, 22 (04) : S9 - S14
  • [2] Pregabalin augmentation to antidepressants in patients with major depressive disorder
    Pae, Chi-Un
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (03): : 577 - 578
  • [3] Organising the front line: Is there a rationale for the first-line pharmacotherapy of major depressive disorder?
    Baune, Bernhard T.
    Boyce, Philip
    Morris, Grace
    Hamilton, Amber
    Bassett, Darryl
    Hopwood, Malcolm
    Mulder, Roger
    Parker, Gordon
    Porter, Richard
    Singh, Ajeet B.
    Outhred, Tim
    Das, Pritha
    Malhi, Gin S.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 (04): : 279 - 281
  • [4] Augmentation strategies in the treatment of major depressive disorder
    Bise, S.
    Kurtovic, B.
    Begic, D.
    Cemalovic, O.
    [J]. EUROPEAN PSYCHIATRY, 2016, 33 : S407 - S407
  • [5] Periodontal status and the efficacy of the first-line treatment of major depressive disorder
    Jelavic, Silvana
    Bajic, Zarko
    Filipcic, Ivona Simunovic
    Culina, Ivana Jurcic
    Filipcic, Igor
    Aurer, Andrej
    [J]. CLINICAL AND EXPERIMENTAL DENTAL RESEARCH, 2022, 8 (01): : 366 - 373
  • [6] Managing Partial Response or Nonresponse: Switching, Augmentation, and Combination Strategies for Major Depressive Disorder
    Papakostas, George I.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 : 16 - 25
  • [7] Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder
    Sato, Yasushi
    Yasui-Furukori, Norio
    Nakagami, Taku
    Saito, Manabu
    Kaneko, Sunao
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (03): : 416 - 418
  • [8] Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder
    Cha, Danielle S.
    Luo, Xinyi
    Ahmed, Juhie
    Becirovic, Larissa
    Cha, Rebekah H.
    McIntyre, Roger S.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (09) : 777 - 783
  • [9] Augmentation strategies for inadequate response in major depressive disorder
    Dilbaz, Nesrin
    Cavus, Sercin Yalcin
    [J]. KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 20 (0M): : S4 - S14
  • [10] Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder:: A systematic review
    Ruhe, Henricus G.
    Huyser, Jochanan
    Swinkels, Jan A.
    Schene, Aart H.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (12) : 1836 - 1855
12345